Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment

Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment

Pulmonary arterial hypertension (PAH) drug therapy including prostanoids, endothelin receptor antagonists, type 5 phosphodiesterase inhibitors, can improve the possibilities for treatment and control of this progressive and irreversible disease. The modern research vector aims at exploring the poten...

Full description

Bibliographic Details
Main Authors:	I E Chazova, T V Martynyuk
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2013-12-01
Series:	Системные гипертензии
Subjects:	pulmonary arterial hypertension nitric oxide guanylatecyclase stimulators riociguat phosphodiesterase type 5 inhibitors
Online Access:	https://syst-hypertension.ru/2075-082X/article/view/28994

Similar Items

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
by: E. V. Filippov
Published: (2020-12-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z S Valieva, et al.
Published: (2018-04-01)

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z.S. Valieva, et al.
Published: (2018-04-01)

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
by: H. A. Ghofrani, et al.
Published: (2009-03-01)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
by: Lian TY, et al.
Published: (2017-04-01)

Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry
by: I E Chazova, et al.
Published: (2019-09-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
by: Alberto M. Marra, et al.
Published: (2018-12-01)

Possibility of complex medicamental and endovascular treatment of pulmonary hypertension in Takayasu arteritis with predominant pulmonary arteries’ lesion
by: T. V. Маrtynuk, et al.
Published: (2020-06-01)

Treatment of patients with chronic thromboembolic pulmonary hypertension: focus on riociguat
by: Smith ZR, et al.
Published: (2016-06-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension
by: Eckhard Mayer, et al.
Published: (2014-01-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
by: John W. Swisher, PhD, MD, et al.
Published: (2017-01-01)

A patient with severe idiopathic pulmonary arterial hypertension: Is there a way out?
by: N A Tsareva, et al.
Published: (2017-09-01)

New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations
by: T. V. Martynyuk, et al.
Published: (2010-04-01)

Sildenafil in pediatric pulmonary arterial hypertension
by: A K Dhariwal, et al.
Published: (2015-01-01)

Experience of the management of patients with pulmonary hypertension in the Republic of Karelia
by: Vadim A Ryabkov, et al.
Published: (2019-09-01)

Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension
by: Anne M Keogh, et al.
Published: (2008-10-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
by: Vallerie V. McLaughlin, et al.
Published: (2017-12-01)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Survival of patients with pulmonary arterial hypertension during therapy PAH-specific drugs
by: D Yu Platonov, et al.
Published: (2017-12-01)

One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease
by: A.C. Barreto, et al.
Published: (2005-02-01)

July 2013 pulmonary journal club
by: Mathew M
Published: (2013-07-01)

The first Russian experience of sildenafil application in patients with idiopathic pulmonary hypertension
by: Z Kh Dadacheva, et al.
Published: (2015-09-01)

The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1): study protocol and review of literature
by: Afif EL-Khuffash, et al.
Published: (2018-12-01)

Clinical case: combination therapy with iloprost and sildenafil in the treatment of idiopathic pulmonary hypertension
by: I N Zavyrylina, et al.
Published: (2015-06-01)

High-altitude pulmonary hypertension
by: X-Q. Xu, et al.
Published: (2009-03-01)

Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results
by: A A Shmalts, et al.
Published: (2018-06-01)

Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results
by: Shmalts А.А., et al.
Published: (2018-05-01)

Comparison Between the Acute Pulmonary Vascular Effects of Oxygen with Nitric Oxide and Sildenafil
by: Ronald W. Day
Published: (2015-03-01)

Pharmacological test with sildenafil at pulmonary hypertension assessing in children with congenital heart diseases
by: O. S. Yanulevich, et al.
Published: (2010-10-01)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
by: Tatsuo Aoki, et al.
Published: (2020-08-01)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
by: Munish Sharma, et al.
Published: (2021-04-01)

Inhibition of PDE5 restores depressed baroreflex sensitivity in renovascular hypertensive rats
by: Clenia O Cavalcanti, et al.
Published: (2016-01-01)

Inhaled therapy for the management of perioperative pulmonary hypertension
by: C A Thunberg, et al.
Published: (2015-01-01)

Rapidly progressive idiopathic pulmonary hypertension in a child
by: D. I. Sadykova, et al.
Published: (2016-03-01)

Favorable Evolution of a Patient with Thromboembolic Pulmonary Hypertension
by: Nedelcu Cristina, et al.
Published: (2017-05-01)